<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/68606">
      <dc:title>Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients</dc:title>
      <dc:creator>González Salvatierra, Sheila</dc:creator>
      <dc:creator>Martínez Heredia, Luis</dc:creator>
      <dc:creator>Muñoz Torres, Manuel Eduardo</dc:creator>
      <dc:creator>Riquelme Gallego, Blanca</dc:creator>
      <dc:subject>Biomarker</dc:subject>
      <dc:subject>Diabetic kidney disease</dc:subject>
      <dc:subject>Kidney function impairment</dc:subject>
      <dc:subject>Type 2 diabetes</dc:subject>
      <dc:subject>Osteoglycin</dc:subject>
      <dc:description>Osteoglycin (OGN) could be a biomarker of mild kidney function impairment in type 2 diabetes (T2D). Our study aimed to determine the association between serum OGN and impaired kidney&#xd;
function risk in T2D patients and to analyze its potential role as an estimator of kidney disturbances&#xd;
in this population. This cross-sectional study included 147 T2D patients (65 ± 8 years, 58.5% males),&#xd;
and 75 healthy controls (63 ± 10 years, 36% males). Circulating OGN levels were determined by&#xd;
ELISA. Linear regression modeling was performed to determine the variables influencing circulating&#xd;
OGN, and an ROC curve was plotted to assess the usefulness of OGN as an estimator of diabetic&#xd;
kidney disease risk. Circulating OGN was significantly increased in T2D patients compared to&#xd;
controls (18.41 (14.45–23.27) ng/mL vs. 8.74 (7.03–12.35) ng/mL; p &lt; 0.001). We found a progressive&#xd;
increase in serum OGN according to the severity of kidney impairment in T2D patients (normal&#xd;
kidney function: 16.14 (12.13–20.48) ng/mL; mildly impaired kidney function: 19.15 (15.78–25.90)&#xd;
ng/mL; moderate impaired kidney function: 21.80 (15.06–29.22) ng/mL; p = 0.006). Circulating OGN&#xd;
was an independent estimator of mildly impaired kidney function risk in T2D patients. We suggest&#xd;
that serum OGN could act as an albuminuria-independent biomarker of incipient kidney dysfunction&#xd;
in T2D patients.</dc:description>
      <dc:date>2021-05-21T08:11:29Z</dc:date>
      <dc:date>2021-05-21T08:11:29Z</dc:date>
      <dc:date>2021</dc:date>
      <dc:type>info:eu-repo/semantics/article</dc:type>
      <dc:identifier>González-Salvatierra, S.; García-Fontana, C.; Andújar-Vera, F.; Grau-Perales, A.B.; Martínez-Heredia, L.; Avilés-Pérez, M.D.; Hayón-Ponce, M.; Iglesias-Baena, I.; Riquelme-Gallego, B.; Muñoz-Torres, M.; et al. Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients. J. Clin. Med. 2021, 10, 2209. https://doi.org/jcm10102209</dc:identifier>
      <dc:identifier>http://hdl.handle.net/10481/68606</dc:identifier>
      <dc:identifier>jcm10102209</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>
      <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
      <dc:rights>Atribución 3.0 España</dc:rights>
      <dc:publisher>MDPI</dc:publisher>
   </ow:Publication>
</rdf:RDF>